A journey through infectious risk associated with ruxolitinib
Summary Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. Despite its efficacy and beyond its well described haematological tox...
Saved in:
| Published in | British journal of haematology Vol. 187; no. 3; pp. 286 - 295 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Blackwell Publishing Ltd
01.11.2019
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0007-1048 1365-2141 1365-2141 |
| DOI | 10.1111/bjh.16174 |
Cover
| Abstract | Summary
Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. Despite its efficacy and beyond its well described haematological toxicity, a peculiar immunosuppressive effect emerged as our clinical experience grew, both within and outside of a clinical trial setting. Definite and negative interactions with multiple pathways of the immune system of patients have been reported so far, involving both adaptive and innate immune responses. These pathophysiological mechanisms may contribute to the increased risk of reactivation of silent infections (e.g., tuberculosis, hepatitis B virus and varicella zoster virus) that have been associated with the drug. Even though such infectious events may be fatal or may lead to significant impairment of organ function, compromising the eligibility of patients for an allotransplant procedure, there are no dedicated guidelines that may help us in assessing and managing the risk of developing serious infections. On this basis, our aim for the present work was to review the current knowledge on the pathophysiological mechanisms through which ruxolitinib may exert its immunosuppressive effect, and to illustrate our personal approach to the management of three peculiar clinical scenarios, for which a risk‐based algorithm is suggested. |
|---|---|
| AbstractList | Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. Despite its efficacy and beyond its well described haematological toxicity, a peculiar immunosuppressive effect emerged as our clinical experience grew, both within and outside of a clinical trial setting. Definite and negative interactions with multiple pathways of the immune system of patients have been reported so far, involving both adaptive and innate immune responses. These pathophysiological mechanisms may contribute to the increased risk of reactivation of silent infections (e.g., tuberculosis, hepatitis B virus and varicella zoster virus) that have been associated with the drug. Even though such infectious events may be fatal or may lead to significant impairment of organ function, compromising the eligibility of patients for an allotransplant procedure, there are no dedicated guidelines that may help us in assessing and managing the risk of developing serious infections. On this basis, our aim for the present work was to review the current knowledge on the pathophysiological mechanisms through which ruxolitinib may exert its immunosuppressive effect, and to illustrate our personal approach to the management of three peculiar clinical scenarios, for which a risk-based algorithm is suggested. Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. Despite its efficacy and beyond its well described haematological toxicity, a peculiar immunosuppressive effect emerged as our clinical experience grew, both within and outside of a clinical trial setting. Definite and negative interactions with multiple pathways of the immune system of patients have been reported so far, involving both adaptive and innate immune responses. These pathophysiological mechanisms may contribute to the increased risk of reactivation of silent infections (e.g., tuberculosis, hepatitis B virus and varicella zoster virus) that have been associated with the drug. Even though such infectious events may be fatal or may lead to significant impairment of organ function, compromising the eligibility of patients for an allotransplant procedure, there are no dedicated guidelines that may help us in assessing and managing the risk of developing serious infections. On this basis, our aim for the present work was to review the current knowledge on the pathophysiological mechanisms through which ruxolitinib may exert its immunosuppressive effect, and to illustrate our personal approach to the management of three peculiar clinical scenarios, for which a risk-based algorithm is suggested.Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. Despite its efficacy and beyond its well described haematological toxicity, a peculiar immunosuppressive effect emerged as our clinical experience grew, both within and outside of a clinical trial setting. Definite and negative interactions with multiple pathways of the immune system of patients have been reported so far, involving both adaptive and innate immune responses. These pathophysiological mechanisms may contribute to the increased risk of reactivation of silent infections (e.g., tuberculosis, hepatitis B virus and varicella zoster virus) that have been associated with the drug. Even though such infectious events may be fatal or may lead to significant impairment of organ function, compromising the eligibility of patients for an allotransplant procedure, there are no dedicated guidelines that may help us in assessing and managing the risk of developing serious infections. On this basis, our aim for the present work was to review the current knowledge on the pathophysiological mechanisms through which ruxolitinib may exert its immunosuppressive effect, and to illustrate our personal approach to the management of three peculiar clinical scenarios, for which a risk-based algorithm is suggested. Summary Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. Despite its efficacy and beyond its well described haematological toxicity, a peculiar immunosuppressive effect emerged as our clinical experience grew, both within and outside of a clinical trial setting. Definite and negative interactions with multiple pathways of the immune system of patients have been reported so far, involving both adaptive and innate immune responses. These pathophysiological mechanisms may contribute to the increased risk of reactivation of silent infections (e.g., tuberculosis, hepatitis B virus and varicella zoster virus) that have been associated with the drug. Even though such infectious events may be fatal or may lead to significant impairment of organ function, compromising the eligibility of patients for an allotransplant procedure, there are no dedicated guidelines that may help us in assessing and managing the risk of developing serious infections. On this basis, our aim for the present work was to review the current knowledge on the pathophysiological mechanisms through which ruxolitinib may exert its immunosuppressive effect, and to illustrate our personal approach to the management of three peculiar clinical scenarios, for which a risk‐based algorithm is suggested. |
| Author | Rumi, Elisa Bonifacio, Massimiliano Sant’Antonio, Emanuela Breccia, Massimo |
| Author_xml | – sequence: 1 givenname: Emanuela orcidid: 0000-0001-5393-0381 surname: Sant’Antonio fullname: Sant’Antonio, Emanuela email: santantonioemanuela@gmail.com organization: Azienda USL Toscana Nord Ovest – sequence: 2 givenname: Massimiliano surname: Bonifacio fullname: Bonifacio, Massimiliano organization: University of Verona – sequence: 3 givenname: Massimo orcidid: 0000-0003-1163-6162 surname: Breccia fullname: Breccia, Massimo organization: University Sapienza – sequence: 4 givenname: Elisa orcidid: 0000-0002-7572-9504 surname: Rumi fullname: Rumi, Elisa organization: Fondazione IRCCS Policlinico San Matteo, University of Pavia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31468506$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kD1PwzAURS1URD9g4A-gSCyAFOpnx447MJQKKKgSC8yW47rUJU2Knaj03-N-wFABXt5y3vW7p40aRVkYhE4BX0N43Ww2vQYOaXKAWkA5iwkk0EAtjHEaA05EE7W9n2EMFDM4Qk0KCRcM8xa66UezsnaFWUXV1JX12zSyxcToypa1j5z175HyvtRWVWYcLW01jVz9Wea2soXNjtHhROXenOxmB73e370MhvHo-eFx0B_FmgqRxFpkgggRTtTQ42OsRI_w3hhEwrkWIiM0FUCzSaoZD5dxaoClDCuWEpqkWtMOutrm1sVCrZYqz-XC2blyKwlYrh3I4EBuHAT4YgsvXPlRG1_JufXa5LkqTCglCREUIASv0fM9dCMjVJGE4h4TwMiaOttRdTY345-vvy0GoLsFtCu9d2Yita1UUFhUTtn81xsv9zb-67NLX9rcrP4G5e3TcLvxBZoknUA |
| CitedBy_id | crossref_primary_10_1007_s00277_022_04851_6 crossref_primary_10_1002_hon_2769 crossref_primary_10_1007_s11030_023_10742_3 crossref_primary_10_1016_j_jaad_2021_06_002 crossref_primary_10_1080_17474086_2020_1733406 crossref_primary_10_4254_wjh_v15_i11_1188 crossref_primary_10_1080_10428194_2022_2057491 crossref_primary_10_1186_s12916_024_03421_z crossref_primary_10_1007_s11864_020_00734_y crossref_primary_10_1016_j_jfma_2020_08_021 crossref_primary_10_3390_cancers12113132 crossref_primary_10_1080_25785826_2022_2139317 crossref_primary_10_1097_MD_0000000000037653 crossref_primary_10_1007_s00277_020_04067_6 crossref_primary_10_3389_fimmu_2021_750346 crossref_primary_10_1111_tid_13401 crossref_primary_10_1007_s10544_023_00680_0 crossref_primary_10_1182_blood_2020006075 crossref_primary_10_1007_s12185_020_02861_6 crossref_primary_10_14309_crj_0000000000000674 crossref_primary_10_1038_s41375_020_0891_0 crossref_primary_10_1097_CCE_0000000000000138 crossref_primary_10_1111_tid_14283 crossref_primary_10_3389_fonc_2023_1163175 crossref_primary_10_1007_s10875_022_01257_x crossref_primary_10_1007_s00277_019_03847_z crossref_primary_10_12998_wjcc_v9_i20_5352 crossref_primary_10_1038_s41392_021_00791_1 crossref_primary_10_1080_10428194_2020_1832671 |
| Cites_doi | 10.1371/journal.ppat.1006740 10.1155/2015/284168 10.1016/S1473-3099(01)00172-4 10.3324/haematol.2009.020412 10.1038/leu.2015.212 10.1111/bjh.13519 10.1016/j.hoc.2017.04.002 10.1182/blood-2015-12-684399 10.1056/NEJMoa1409002 10.4084/mjhid.2014.026 10.1124/dmd.117.076034 10.1053/j.gastro.2014.10.039 10.1002/art.40187 10.1177/1060028018758431 10.1111/j.1600-065X.2008.00754.x 10.1007/s00277-014-2183-0 10.1002/hon.2509 10.3109/10428194.2014.963082 10.1007/s00277-018-3405-7 10.1182/blood-2016-02-700013 10.1038/leu.2016.148 10.1080/10428194.2019.1579323 10.1128/AAC.45.2.382-392.2001 10.1056/NEJMoa1002028 10.1182/blood.V122.21.1596.1596 10.1111/bjh.13373 10.1007/s00277-013-1936-5 10.1097/00029330-200809020-00005 10.1038/sj.bjc.6604935 10.1182/blood.V126.23.2838.2838 10.1016/S0145-2126(99)00120-4 10.2169/internalmedicine.9165-17 10.1182/blood-2016-10-695940 10.1186/1756-0500-5-552 10.1186/gb-2004-5-12-253 10.1080/23744235.2017.1390248 10.1016/j.hemonc.2017.07.002 10.1016/j.dld.2017.03.004 10.1093/cid/ciw778 10.4049/jimmunol.165.4.2271 10.1002/hon.2429 10.1007/s00277-016-2684-0 10.1002/ajh.24688 10.1016/j.cmi.2018.02.009 10.1038/leu.2014.104 10.1182/blood-2013-03-484642 10.1034/j.1600-0609.2000.90262.x 10.1016/S1470-2045(16)30558-7 10.1182/blood-2013-12-543736 10.1155/2016/2389038 10.1007/s00277-015-2447-3 10.1007/s11899-014-0227-0 10.1002/ajh.24976 10.1038/leu.2016.155 10.3324/haematol.2016.143644 10.1200/JCO.2014.57.6652 10.1111/j.1574-6976.2012.00331.x 10.3324/haematol.2014.115840 10.3324/haematol.2016.143677 10.1016/j.bbmt.2018.09.003 10.1186/1471-2334-9-15 10.1016/j.jaut.2017.06.010 10.1080/14760584.2017.1395703 10.1111/bjh.14382 10.1016/j.ijid.2019.01.002 10.1158/0008-5472.CAN-14-3198 10.1053/j.gastro.2017.02.009 10.1038/377065a0 10.2169/internalmedicine.55.5529 10.1007/s00228-001-0396-3 10.1182/bloodadvances.2017007526 10.1016/j.jinf.2015.04.015 10.1016/j.leukres.2016.02.004 10.1038/leu.2013.296 10.1038/s41375-019-0388-x 10.1038/leu.2013.235 |
| ContentType | Journal Article |
| Copyright | 2019 British Society for Haematology and John Wiley & Sons Ltd 2019 British Society for Haematology and John Wiley & Sons Ltd. Copyright © 2019 John Wiley & Sons Ltd |
| Copyright_xml | – notice: 2019 British Society for Haematology and John Wiley & Sons Ltd – notice: 2019 British Society for Haematology and John Wiley & Sons Ltd. – notice: Copyright © 2019 John Wiley & Sons Ltd |
| DBID | AAYXX CITATION NPM 7T5 H94 K9. 7X8 ADTOC UNPAY |
| DOI | 10.1111/bjh.16174 |
| DatabaseName | CrossRef PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic AIDS and Cancer Research Abstracts CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2141 |
| EndPage | 295 |
| ExternalDocumentID | 10.1111/bjh.16174 31468506 10_1111_bjh_16174 BJH16174 |
| Genre | reviewArticle Journal Article Review |
| GrantInformation_xml | – fundername: Novartis Farma |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1KJ 1OB 1OC 23N 24P 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAYEP AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHEFC AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EGARE EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IH2 IHE IX1 J0M J5H K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K V9Y VH1 W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION NPM YIN 7T5 H94 K9. 7X8 ADTOC UNPAY |
| ID | FETCH-LOGICAL-c3884-c8b8288161c196d0a89269d18466c88b237813bf7c5614663e15750a572347cc3 |
| IEDL.DBID | UNPAY |
| ISSN | 0007-1048 1365-2141 |
| IngestDate | Tue Aug 19 19:48:08 EDT 2025 Fri Jul 11 11:30:45 EDT 2025 Mon Oct 06 17:39:39 EDT 2025 Wed Feb 19 02:31:34 EST 2025 Thu Apr 24 23:04:54 EDT 2025 Wed Oct 01 01:36:11 EDT 2025 Wed Jan 22 16:37:45 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | infection myelofibrosis ruxolitinib management polycythaemia vera |
| Language | English |
| License | 2019 British Society for Haematology and John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3884-c8b8288161c196d0a89269d18466c88b237813bf7c5614663e15750a572347cc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-1163-6162 0000-0002-7572-9504 0000-0001-5393-0381 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16174 |
| PMID | 31468506 |
| PQID | 2309581524 |
| PQPubID | 36395 |
| PageCount | 10 |
| ParticipantIDs | unpaywall_primary_10_1111_bjh_16174 proquest_miscellaneous_2283113474 proquest_journals_2309581524 pubmed_primary_31468506 crossref_citationtrail_10_1111_bjh_16174 crossref_primary_10_1111_bjh_16174 wiley_primary_10_1111_bjh_16174_BJH16174 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | November 2019 2019-11-00 2019-Nov 20191101 |
| PublicationDateYYYYMMDD | 2019-11-01 |
| PublicationDate_xml | – month: 11 year: 2019 text: November 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | British journal of haematology |
| PublicationTitleAlternate | Br J Haematol |
| PublicationYear | 2019 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | 2017; 85 2017; 1 2015; 71 2015; 148 2019; 98 2017; 49 2015; 75 2015; 100 2002; 57 2017; 45 2016; 101 2013; 122 2016; 30 2004; 5 2016; 2016 2017; 152 1995; 377 2014; 28 2001; 45 2015; 372 2017; 31 2015; 171 2019; 25 2016; 43 2000; 165 2014; 9 2014; 6 2014; 93 2015b; 33 2018; 36 2014; 123 2017; 129 2015; 56 2017; 64 2015; 126 2017; 69 2019; 33 2015; 94 2015; 169 2000; 65 2010; 363 2002; 2 1999; 23 2016; 95 2016; 128 2017; 130 2016; 127 2017; 176 2012; 36 2008; 121 2016; 55 2018; 24 2019; 80 2017; 93 2017; 92 2015; 29 2015a; 100 2015; 159 2017; 16 2017; 10 2017; 13 2015; 2015 2009; 100 2019 2009; 9 2017 2018; 52 2017; 18 2018; 50 2009; 228 2012; 5 2010; 95 2018; 57 e_1_2_11_70_1 e_1_2_11_72_1 e_1_2_11_32_1 e_1_2_11_55_1 e_1_2_11_78_1 e_1_2_11_30_1 e_1_2_11_57_1 e_1_2_11_36_1 e_1_2_11_51_1 e_1_2_11_74_1 e_1_2_11_13_1 e_1_2_11_34_1 e_1_2_11_53_1 e_1_2_11_76_1 e_1_2_11_11_1 e_1_2_11_6_1 e_1_2_11_27_1 e_1_2_11_48_1 e_1_2_11_2_1 e_1_2_11_60_1 e_1_2_11_81_1 e_1_2_11_20_1 e_1_2_11_66_1 e_1_2_11_47_1 e_1_2_11_68_1 e_1_2_11_24_1 e_1_2_11_41_1 e_1_2_11_62_1 e_1_2_11_8_1 e_1_2_11_22_1 Hultcrantz M. (e_1_2_11_29_1) 2015; 100 e_1_2_11_43_1 e_1_2_11_64_1 e_1_2_11_17_1 Malkan U.Y. (e_1_2_11_45_1) 2017; 10 e_1_2_11_15_1 e_1_2_11_59_1 e_1_2_11_38_1 e_1_2_11_19_1 e_1_2_11_50_1 e_1_2_11_71_1 e_1_2_11_10_1 e_1_2_11_31_1 e_1_2_11_56_1 e_1_2_11_77_1 e_1_2_11_58_1 e_1_2_11_79_1 e_1_2_11_14_1 Keizer S. (e_1_2_11_33_1) 2015; 159 e_1_2_11_35_1 e_1_2_11_52_1 e_1_2_11_73_1 e_1_2_11_12_1 e_1_2_11_54_1 e_1_2_11_75_1 e_1_2_11_7_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_49_1 Al‐Ali H.K. (e_1_2_11_4_1) 2017; 130 e_1_2_11_61_1 e_1_2_11_80_1 e_1_2_11_21_1 e_1_2_11_44_1 e_1_2_11_67_1 e_1_2_11_46_1 e_1_2_11_69_1 e_1_2_11_25_1 e_1_2_11_40_1 e_1_2_11_63_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_42_1 e_1_2_11_65_1 e_1_2_11_18_1 e_1_2_11_16_1 e_1_2_11_37_1 e_1_2_11_39_1 |
| References_xml | – volume: 50 start-page: 381 year: 2018 end-page: 387 article-title: Infectious complications in patients on treatment with ruxolitinib: case report and review of the literature publication-title: Infectious Diseases – volume: 148 start-page: 215 year: 2015 end-page: 219 article-title: American Gastroenterological Association Institute Guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy publication-title: Gastroenterology – volume: 24 start-page: S53 year: 2018 end-page: S70 article-title: ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors) publication-title: Clinical Microbiology and Infection – volume: 100 start-page: 666 year: 2015a article-title: Myeloproliferative neoplasms and infections; a population‐based study on 9,665 patients with myeloproliferative neoplasms diagnosed in Sweden 1987–2009 publication-title: Haematologica – volume: 33 start-page: 844 year: 2019 end-page: 862 article-title: Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL) publication-title: Leukemia – volume: 169 start-page: 824 year: 2015 end-page: 833 article-title: JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms publication-title: British Journal of Haematology – volume: 126 start-page: 2838 year: 2015 article-title: Ruxolitinib treatment induces a transition of classical to non‐classical monocytes in patients with myelofibrosis publication-title: Blood – volume: 93 start-page: 339 year: 2017 end-page: 347 article-title: Ruxolitinib‐associated infections: a systematic review and meta‐analysis publication-title: American Journal of Hematology – volume: 71 start-page: S47 year: 2015 end-page: S53 article-title: Varicella zoster virus immunity: a primer publication-title: Journal of Infection – volume: 2 start-page: 43 year: 2002 end-page: 50 article-title: Immunology of hepatitis B infection publication-title: Lancet Infectious Diseases – volume: 45 start-page: 1035 year: 2017 end-page: 1043 article-title: Inhibitory effects of selected antituberculosis drugs on common human hepatic cytochrome P450 and UDP‐glucuronosyltransferase enzymes publication-title: Drug Metabolism and Disposition: The Biological Fate of Chemicals – volume: 101 start-page: 1065 year: 2016 end-page: 1073 article-title: Safety and efficacy of ruxolitinib in an open‐label, multicenter, single‐arm phase 3b expanded‐access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial publication-title: Haematologica – volume: 100 start-page: 479 year: 2015 end-page: 488 article-title: Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3‐year follow‐up of COMFORT‐I publication-title: Haematologica – volume: 101 start-page: 821 year: 2016 end-page: 829 article-title: Ruxolitinib versus best available therapy in patients with polycythemia vera: 80‐week follow‐up from the RESPONSE trial publication-title: Haematologica – volume: 36 start-page: 514 year: 2012 end-page: 532 article-title: Mycobacterium tuberculosis: success through dormancy publication-title: FEMS Microbiology Reviews – volume: 10 start-page: 7304 year: 2017 end-page: 7307 article-title: A myelofibrosis case that develops mycobacterial infection after ruxolitinib treatment publication-title: International Journal of Clinical and Experimental Medicine – volume: 30 start-page: 2119 year: 2016 end-page: 2123 article-title: The JAK inhibitor ruxolitinib impairs dendritic cell migration via off‐target inhibition of ROCK publication-title: Leukemia – volume: 33 start-page: 2288 year: 2015b end-page: 2295 article-title: Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population‐based study publication-title: Journal of Clinical Oncology – volume: 176 start-page: 76 year: 2017 end-page: 85 article-title: The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF) publication-title: British Journal of Haematology – volume: 23 start-page: 983 year: 1999 end-page: 985 article-title: Resident bone marrow macrophages in idiopathic (primary) myelofibrosis (IMF): a histochemical and morphometric study on sequential trephine biopsies publication-title: Leukemia Research – volume: 57 start-page: 799 year: 2002 end-page: 804 article-title: Isoniazid is a mechanism‐based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes publication-title: European Journal of Clinical Pharmacology – volume: 13 year: 2017 article-title: Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors publication-title: PLoS Path – volume: 159 start-page: A8650 year: 2015 article-title: Fatal tuberculosis during treatment with ruxolitinib publication-title: Nederlands Tijdschrift voor Geneeskunde – year: 2017 article-title: Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report publication-title: Hematology/Oncology and Stem Cell Therapy – volume: 127 start-page: 1666 year: 2016 end-page: 1675 article-title: Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis publication-title: Blood – volume: 152 start-page: 1297 year: 2017 end-page: 1309 article-title: Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions publication-title: Gastroenterology – start-page: 1 year: 2019 end-page: 9 article-title: Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis publication-title: Leukemia and Lymphoma – volume: 36 start-page: 561 year: 2018 end-page: 569 article-title: Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: a multicenter study on 446 patients publication-title: Hematological Oncology – volume: 64 start-page: 111 year: 2017 end-page: 115 article-title: Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: diagnosis of Tuberculosis in Adults and Children publication-title: Clinical Infectious Diseases – volume: 6 year: 2014 article-title: Tuberculosis in patients with haematological malignancies publication-title: Mediterranean Journal of Hematology and Infectious Diseases – volume: 29 start-page: 2062 year: 2015 end-page: 2068 article-title: Ruxolitinib in corticosteroid‐refractory graft‐versus‐host disease after allogeneic stem cell transplantation: a multicenter survey publication-title: Leukemia – volume: 49 start-page: 719 year: 2017 article-title: Occult hepatitis B infection reactivation after ruxolitinib therapy publication-title: Digestive and Liver Disease – volume: 92 start-page: E74 year: 2017 end-page: E75 article-title: Varicella‐zoster virus meningoencephalitis in a patient treated with ruxolitinib publication-title: American Journal of Hematology – volume: 69 start-page: 1969 year: 2017 end-page: 1977 article-title: The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial publication-title: Arthritis and Rheumatology – volume: 45 start-page: 382 year: 2001 end-page: 392 article-title: Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A publication-title: Antimicrobial Agents and Chemotherapy – volume: 55 start-page: 1341 year: 2016 end-page: 1344 article-title: Elevation of the hepatitis B virus DNA during the treatment of polycythemia vera with the JAK kinase inhibitor ruxolitinib publication-title: Internal Medicine – volume: 95 start-page: 1216 year: 2010 end-page: 1220 article-title: Autoimmunity and the risk of myeloproliferative neoplasms publication-title: Haematologica – volume: 5 start-page: 253 year: 2004 article-title: The Janus kinases (Jaks) publication-title: Genome Biology – volume: 1 start-page: 1533 year: 2017 end-page: 1536 article-title: Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis publication-title: Blood Advances – volume: 28 start-page: 449 year: 2014 end-page: 451 article-title: Rapid and long‐lasting decrease of T‐regulatory cells in patients with myelofibrosis treated with ruxolitinib publication-title: Leukemia – volume: 377 start-page: 65 year: 1995 end-page: 68 article-title: Mutations of JAK‐3 gene in patients with autosomal severe combined immune deficiency (SCID) publication-title: Nature – volume: 165 start-page: 2271 year: 2000 end-page: 2277 article-title: NF‐kappa B as a central mediator in the induction of TGF‐beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis publication-title: Journal of Immunology – volume: 57 start-page: 1297 year: 2018 end-page: 1300 article-title: Fatal disseminated tuberculosis during treatment with ruxolitinib plus prednisolone in a patient with primary myelofibrosis: A case report and review of the literature publication-title: Internal Medicine – volume: 363 start-page: 1117 year: 2010 end-page: 1127 article-title: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis publication-title: New England Journal of Medicine – volume: 28 start-page: 1750 year: 2014 end-page: 1751 article-title: Disseminated tuberculosis associated with ruxolitinib publication-title: Leukemia – volume: 16 start-page: 1217 year: 2017 end-page: 1230 article-title: Studies with herpes zoster vaccines in immune compromised patients publication-title: Expert Review of Vaccines – volume: 85 start-page: 58 year: 2017 end-page: 63 article-title: Inflammation and myeloproliferative neoplasms publication-title: Journal of Autoimmunity – volume: 36 start-page: 285 year: 2018 end-page: 290 article-title: Efficacy and safety of ruxolitinib in intermediate‐1 IPSS risk myelofibrosis patients: results from an independent study publication-title: Hematological Oncology – volume: 93 start-page: 1075 year: 2014 end-page: 1076 article-title: Hepatitis B virus reactivation associated with ruxolitinib publication-title: Annals of Hematology – volume: 65 start-page: 104 year: 2000 end-page: 108 article-title: Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis publication-title: European Journal of Haematology – volume: 123 start-page: 3832 year: 2014 end-page: 3842 article-title: Activity of therapeutic JAK 1/2 blockade in graft‐versus‐host disease publication-title: Blood – volume: 2015 start-page: 284168 year: 2015 article-title: Ruxolitinib associated tuberculosis presenting as a neck lump publication-title: Case Reports in Infectious Diseases – volume: 2016 start-page: 2389038 year: 2016 article-title: Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib publication-title: Case Reports in Hematology – volume: 129 start-page: 667 year: 2017 end-page: 679 article-title: Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms publication-title: Blood – volume: 30 start-page: 1701 year: 2016 end-page: 1707 article-title: Long‐term findings from COMFORT‐II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis publication-title: Leukemia – volume: 94 start-page: 1441 year: 2015 end-page: 1450 article-title: Antiviral prophylaxis in patients with solid tumours and haematological malignancies–update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) publication-title: Annals of Hematology – volume: 9 start-page: 331 year: 2014 end-page: 339 article-title: An immune dysregulation in MPN publication-title: Current Hematologic Malignancy Reports – volume: 128 start-page: 60 year: 2016 end-page: 71 article-title: Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice publication-title: Blood – volume: 171 start-page: 60 year: 2015 end-page: 73 article-title: JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells publication-title: British Journal of Haematology – volume: 25 start-page: 265 year: 2019 end-page: 269 article-title: Ruxolitinib as salvage therapy for chronic graft‐versus‐host disease publication-title: Biology of Blood and Marrow Transplantation – volume: 9 start-page: 15 year: 2009 article-title: Poor concordance between interferon‐gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV‐infected individuals publication-title: BMC Infectious Diseases – volume: 228 start-page: 273 year: 2009 end-page: 287 article-title: Janus kinases in immune cell signaling publication-title: Immunological Reviews – volume: 100 start-page: 822 year: 2009 end-page: 828 article-title: Risks of myeloid malignancies in patients with autoimmune conditions publication-title: British Journal of Cancer – volume: 122 start-page: 1596 year: 2013 end-page: 1596 article-title: Efficacy of ruxolitinib in Korean myelofibrosis patients and cases complicated TB lymphadenitis during the treatment publication-title: Blood – volume: 5 start-page: 552 year: 2012 article-title: Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report publication-title: BMC Research Notes – volume: 80 start-page: 134 year: 2019 end-page: 136 article-title: Tuberculosis and atypical mycobacterial infections in ruxolitinib‐treated patients with primary or secondary myelofibrosis or polycythemia vera publication-title: International Journal of Infectious Diseases – volume: 18 start-page: 88 year: 2017 end-page: 99 article-title: Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE‐2): a randomised, open‐label, phase 3b study publication-title: Lancet Oncology – volume: 94 start-page: 519 year: 2015 end-page: 520 article-title: Ruxolitinib‐associated tuberculosis: a case of successful ruxolitinib rechallenge publication-title: Annals of Hematology – volume: 56 start-page: 1528 year: 2015 end-page: 1529 article-title: Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis publication-title: Leukemia and Lymphoma – volume: 31 start-page: 613 year: 2017 end-page: 626 article-title: The development and use of janus kinase 2 inhibitors for the treatment of myeloproliferative neoplasms publication-title: Hematology/Oncology Clinics of North America – volume: 121 start-page: 1781 year: 2008 end-page: 1786 article-title: Involvement of CD4+CD25+ regulatory T cells in the pathogenesis of polycythaemia vera publication-title: Chinese Medical Journal – volume: 122 start-page: 1192 year: 2013 end-page: 1202 article-title: The JAK‐inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo publication-title: Blood – volume: 372 start-page: 426 year: 2015 end-page: 435 article-title: Ruxolitinib versus standard therapy for the treatment of polycythemia vera publication-title: New England Journal of Medicine – volume: 43 start-page: 39 year: 2016 end-page: 43 article-title: Myeloid‐derived suppressor cells in patients with myeloproliferative neoplasm publication-title: Leukemia Research – volume: 75 start-page: 2187 year: 2015 end-page: 2199 article-title: JAK inhibition impairs NK cell function in myeloproliferative neoplasms publication-title: Cancer Research – volume: 95 start-page: 1207 year: 2016 end-page: 1209 article-title: Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib publication-title: Annals of Hematology – volume: 52 start-page: 673 year: 2018 end-page: 680 article-title: Shingrix: the new adjuvanted recombinant herpes zoster vaccine publication-title: Annals of Pharmacotherapy – volume: 98 start-page: 215 year: 2019 end-page: 218 article-title: Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment publication-title: Annals of Hematology – volume: 28 start-page: 225 year: 2014 end-page: 227 article-title: Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis publication-title: Leukemia – volume: 130 start-page: 4204 year: 2017 end-page: 4204 article-title: Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis (N = 2233) publication-title: Blood – volume: 159 start-page: A8650 year: 2015 ident: e_1_2_11_33_1 article-title: Fatal tuberculosis during treatment with ruxolitinib publication-title: Nederlands Tijdschrift voor Geneeskunde – ident: e_1_2_11_21_1 doi: 10.1371/journal.ppat.1006740 – ident: e_1_2_11_64_1 doi: 10.1155/2015/284168 – ident: e_1_2_11_32_1 doi: 10.1016/S1473-3099(01)00172-4 – ident: e_1_2_11_36_1 doi: 10.3324/haematol.2009.020412 – ident: e_1_2_11_80_1 doi: 10.1038/leu.2015.212 – ident: e_1_2_11_34_1 doi: 10.1111/bjh.13519 – ident: e_1_2_11_27_1 doi: 10.1016/j.hoc.2017.04.002 – ident: e_1_2_11_16_1 doi: 10.1182/blood-2015-12-684399 – ident: e_1_2_11_72_1 doi: 10.1056/NEJMoa1409002 – ident: e_1_2_11_6_1 doi: 10.4084/mjhid.2014.026 – ident: e_1_2_11_11_1 doi: 10.1124/dmd.117.076034 – ident: e_1_2_11_59_1 doi: 10.1053/j.gastro.2014.10.039 – ident: e_1_2_11_78_1 doi: 10.1002/art.40187 – ident: e_1_2_11_31_1 doi: 10.1177/1060028018758431 – ident: e_1_2_11_23_1 doi: 10.1111/j.1600-065X.2008.00754.x – ident: e_1_2_11_51_1 doi: 10.1007/s00277-014-2183-0 – ident: e_1_2_11_56_1 doi: 10.1002/hon.2509 – ident: e_1_2_11_14_1 doi: 10.3109/10428194.2014.963082 – ident: e_1_2_11_24_1 doi: 10.1007/s00277-018-3405-7 – ident: e_1_2_11_46_1 doi: 10.1182/blood-2016-02-700013 – ident: e_1_2_11_25_1 doi: 10.1038/leu.2016.148 – ident: e_1_2_11_8_1 doi: 10.1080/10428194.2019.1579323 – ident: e_1_2_11_17_1 doi: 10.1128/AAC.45.2.382-392.2001 – ident: e_1_2_11_73_1 doi: 10.1056/NEJMoa1002028 – ident: e_1_2_11_37_1 doi: 10.1182/blood.V122.21.1596.1596 – ident: e_1_2_11_53_1 doi: 10.1111/bjh.13373 – ident: e_1_2_11_65_1 doi: 10.1007/s00277-013-1936-5 – ident: e_1_2_11_81_1 doi: 10.1097/00029330-200809020-00005 – ident: e_1_2_11_5_1 doi: 10.1038/sj.bjc.6604935 – ident: e_1_2_11_57_1 doi: 10.1182/blood.V126.23.2838.2838 – ident: e_1_2_11_69_1 doi: 10.1016/S0145-2126(99)00120-4 – ident: e_1_2_11_70_1 doi: 10.2169/internalmedicine.9165-17 – ident: e_1_2_11_71_1 doi: 10.1182/blood-2016-10-695940 – ident: e_1_2_11_15_1 doi: 10.1186/1756-0500-5-552 – ident: e_1_2_11_79_1 doi: 10.1186/gb-2004-5-12-253 – ident: e_1_2_11_18_1 doi: 10.1080/23744235.2017.1390248 – ident: e_1_2_11_66_1 doi: 10.1016/j.hemonc.2017.07.002 – ident: e_1_2_11_55_1 doi: 10.1016/j.dld.2017.03.004 – ident: e_1_2_11_40_1 doi: 10.1093/cid/ciw778 – ident: e_1_2_11_58_1 doi: 10.4049/jimmunol.165.4.2271 – ident: e_1_2_11_52_1 doi: 10.1002/hon.2429 – ident: e_1_2_11_9_1 doi: 10.1007/s00277-016-2684-0 – ident: e_1_2_11_20_1 doi: 10.1002/ajh.24688 – ident: e_1_2_11_60_1 doi: 10.1016/j.cmi.2018.02.009 – ident: e_1_2_11_28_1 doi: 10.1038/leu.2014.104 – ident: e_1_2_11_26_1 doi: 10.1182/blood-2013-03-484642 – ident: e_1_2_11_13_1 doi: 10.1034/j.1600-0609.2000.90262.x – volume: 10 start-page: 7304 year: 2017 ident: e_1_2_11_45_1 article-title: A myelofibrosis case that develops mycobacterial infection after ruxolitinib treatment publication-title: International Journal of Clinical and Experimental Medicine – ident: e_1_2_11_54_1 doi: 10.1016/S1470-2045(16)30558-7 – ident: e_1_2_11_67_1 doi: 10.1182/blood-2013-12-543736 – ident: e_1_2_11_2_1 doi: 10.1155/2016/2389038 – ident: e_1_2_11_62_1 doi: 10.1007/s00277-015-2447-3 – volume: 130 start-page: 4204 year: 2017 ident: e_1_2_11_4_1 article-title: Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis (N = 2233) publication-title: Blood – ident: e_1_2_11_7_1 doi: 10.1007/s11899-014-0227-0 – ident: e_1_2_11_43_1 doi: 10.1002/ajh.24976 – ident: e_1_2_11_61_1 doi: 10.1038/leu.2016.155 – ident: e_1_2_11_75_1 doi: 10.3324/haematol.2016.143644 – ident: e_1_2_11_30_1 doi: 10.1200/JCO.2014.57.6652 – ident: e_1_2_11_22_1 doi: 10.1111/j.1574-6976.2012.00331.x – ident: e_1_2_11_74_1 doi: 10.3324/haematol.2014.115840 – ident: e_1_2_11_3_1 doi: 10.3324/haematol.2016.143677 – ident: e_1_2_11_50_1 doi: 10.1016/j.bbmt.2018.09.003 – ident: e_1_2_11_68_1 doi: 10.1186/1471-2334-9-15 – ident: e_1_2_11_42_1 doi: 10.1016/j.jaut.2017.06.010 – ident: e_1_2_11_39_1 doi: 10.1080/14760584.2017.1395703 – ident: e_1_2_11_49_1 doi: 10.1111/bjh.14382 – ident: e_1_2_11_38_1 doi: 10.1016/j.ijid.2019.01.002 – ident: e_1_2_11_63_1 doi: 10.1158/0008-5472.CAN-14-3198 – ident: e_1_2_11_41_1 doi: 10.1053/j.gastro.2017.02.009 – ident: e_1_2_11_44_1 doi: 10.1038/377065a0 – ident: e_1_2_11_35_1 doi: 10.2169/internalmedicine.55.5529 – ident: e_1_2_11_77_1 doi: 10.1007/s00228-001-0396-3 – ident: e_1_2_11_10_1 doi: 10.1182/bloodadvances.2017007526 – ident: e_1_2_11_19_1 doi: 10.1016/j.jinf.2015.04.015 – ident: e_1_2_11_76_1 doi: 10.1016/j.leukres.2016.02.004 – ident: e_1_2_11_48_1 doi: 10.1038/leu.2013.296 – ident: e_1_2_11_47_1 doi: 10.1038/s41375-019-0388-x – volume: 100 start-page: 666 year: 2015 ident: e_1_2_11_29_1 article-title: Myeloproliferative neoplasms and infections; a population‐based study on 9,665 patients with myeloproliferative neoplasms diagnosed in Sweden 1987–2009 publication-title: Haematologica – ident: e_1_2_11_12_1 doi: 10.1038/leu.2013.235 |
| SSID | ssj0013051 |
| Score | 2.453645 |
| SecondaryResourceType | review_article |
| Snippet | Summary
Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its... Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval... |
| SourceID | unpaywall proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 286 |
| SubjectTerms | Algorithms Hepatitis B Immune response Immunosuppression infection Innate immunity management Myelofibrosis Patients polycythaemia vera ruxolitinib Toxicity Tuberculosis Varicella |
| SummonAdditionalLinks | – databaseName: Wiley Online Library - Core collection (SURFmarket) dbid: DR2 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8QwEB7EB48H72O9iMeDL126TdOmiA8qyiLogyj4IJQkm-Kx1MXd4vHrnaRpvUV8aiFTmmZm0m-SmS8AWz7FCSAJGXpaLLww86UnVKY9zWKK8Fb6mc12PzmN2hfh8SW7HIKdqham5IeoF9yMZ9j52ji4kP13Ti5vr5sGnBsu0BaNbDh1FrztIPjMnZYX41QTcscqZLJ46ic__ou-AMxxGC3ynnh-FN3uR-xqfz5Hk3BVdbvMOblrFgPZVC-fGB3_-V1TMOFAKdkrrWgahnQ-AyMnbtt9Fnb3iLU5_UzcuT6kSuIq-sRkpxPh1Kw7xCztkofiyWbW5TdyDi6ODs8P2p47d8FTlPPQU1xiHMaxEwr9s-MLngRR0sFYMIoU5zKgMW9RmcXK0IgiZNEtBH2-YHFAw1gpOg_D-X2uF4GITLAOzViGuCBkPJGB4Fob1j-8oo00YLvSQKocKbk5G6ObVsEJDkdqh6MBG7Vor2Ti-E5opVJj6pyxn2KUlTCOQAWb1-tmdCOzNyJyjUOVGhaglimrRZmFUv31W6gpT2N-1IDN2h5-68K2Ve_PEun-cdveLP1ddBnGEKolZRXkCgwPHgq9inBoINes3b8CX-cB8w priority: 102 providerName: Wiley-Blackwell |
| Title | A journey through infectious risk associated with ruxolitinib |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbjh.16174 https://www.ncbi.nlm.nih.gov/pubmed/31468506 https://www.proquest.com/docview/2309581524 https://www.proquest.com/docview/2283113474 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16174 |
| UnpaywallVersion | publishedVersion |
| Volume | 187 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1365-2141 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1365-2141 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013051 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB6VRQL1AOVR2AqQKRy4ZEniOHEOPSyoaIUEQhUrwSnYjqO2rNLVshGPX8_YcSIttKgSp0TyJHE8D39jj2cA9n2KBiCNGGpaIryo8KUnVKE9zRKK8Fb6hY12PzuPB8Po9IpduTqn5ixMnR-iXXAzmmHttVHwcV7Udr5R9UP5-2fPAPRoDuZjhmC8A_PD84v-dQ16EzQytn5WHcsVRIHLLTTz7OyM9ApmfoTFqhyLx3sxGs0iWDsFnSzDTdP5OvLktldNZU89vcjr-I6_-wRLDp6Sfi1PK_BBl6uwcOY24NfgW59Y6dOPxFX4IU04V3VHTJw6EY7hOidmkZdMqgcbY1f-kuswPPl-eTzwXAUGT1HOI09xiR4Zx04o1NTcFzwN4zRHrzCOFecypAkPqCwSZRKKInjRAcI_X7AkpFGiFP0MnfJPqTeBiEKwnBasQIQQMZ7KUHCtTf4_vKK0dOGg4UKmXHpyUyVjlDVuCg5HZoejC19b0nGdk-NvRFsNKzOnlncZ-lsp4whZsHm3bUaFMrskotQ4VJnJBxSYA7ZIs1GLQPsVag6qMT_uwl4rE2914cCy-N8U2dHpwN58-a8XbkFnOqn0NsKgqdxBB-BHuOME_hn9fQVW |
| linkProvider | Unpaywall |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4tVCr0QFugdHm05nHYS1bZ2E4cCQ60Am0py6ECiQuKbK-jAquAYKN2--s7dpxQKKCqp0TyRHE88znf2DNjgK2Q4gSQMo5IS2TA8lAFUucmMDyhSG9VmLto98FR3D9hB6f8tAXbdS5MVR-iWXCzyHDztQW4XZD-A-Xq4nvXsnM2BS9YjH6KpUTfors9hJD78_ISnGyY8HWFbBxP8-j9v9FfFPMVzJTFtZz8kKPRffbqfj_7r-Gs7ngVdXLZLceqq389qOn4v1_2BuY8LyW7lSG9hZYp5uHlwO-8L8DOLnFmZybEH-1D6jiu8pbYAHUivabNkNjVXXJT_nTBdcW5WoST_b3jz_3AH70QaCoEC7RQ6IoJ7IRGiA5DKdIoTofoDsaxFkJFNBE9qvJE20qiyFpMD3lfKHkSUZZoTd_BdHFVmPdAZC75kOY8R2rAuEhVJIUxtvAfXtFM2tCpVZBpX5fcHo8xymr_BIcjc8PRho1G9LoqxvGY0Gqtx8zj8TZDRyvlArkKNq83zYgkuz0iC4NDldlCQD2bWYsyS5X-m7dQm6HGw7gNm41BPNeFjtPv0xLZp4O-u1n-d9GPMNM_Hhxmh1-Ovq7ALDK3tEqKXIXp8U1p1pAdjdUHB4LfkPoGFA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fT9UwFD4BTAAfQAX0ImoFHnjZze7abl0iDyjcXFGIIZLwQpa26wJ6M2_gLgp_PaddN-WXITxtSc-yruec7jvtOV8B1kOKE0DKOHpaIgNWhCqQujCB4QlFeKvCwmW77-3Hg0O2e8SPJuBDUwtT80O0C27WM9x8bR3cjPLiHy9XP066Fp2zSXjCeCpsQt_2QfR3DyHk_ry8BCcbJjyvkM3jaR-9_je6BTGfwkxVjuTFbzkcXkev7vfTn4fjpuN11snPbjVWXX15g9PxsV_2DOY8LiVbtSE9hwlTvoDpPb_zvgCbW8SZnbkg_mgf0uRxVefEJqgT6TVtcmJXd8lZ9ccl15WnahEO-zvfPw0Cf_RCoKkQLNBCYSgmsBMaXTQPpUijOM0xHIxjLYSKaCJ6VBWJtkyiiFpMD3FfKHkSUZZoTZdgqvxVmldAZCF5TgteIDRgXKQqksIYS_yHVzSTDmw0Ksi05yW3x2MMsyY-weHI3HB0YLUVHdVkHHcJrTR6zLw_nmcYaKVcIFbB5vdtM3qS3R6RpcGhyiwRUM9W1qLMy1r_7VuorVDjYdyBtdYg_teFDaff-yWyj7sDd7P8cNF3MP1tu599_bz_5TXMInBL65rIFZgan1XmDYKjsXrrfOAKMIMFmA |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NT9swFH9iRdrEAfYJRWXyBgcuKUkcJ86BQ0GgqlLRDqvETsF2HG2jClXbCLq_fs-OE6lsQ0g7JZJfEsfvw79nP78HcORTNABpxFDTEuFFhS89oQrtaZZQhLfSL2y0-_gqHk6i0TW7dnVOzVmYOj9Eu-BmNMPaa6Pgs7yo7Xyj6ify5_e-AejRC9iMGYLxDmxOrr4MvtWgN0EjY-tn1bFcQRS43EJrz67PSH_AzC14VZUzsboX0-k6grVT0OUO3DSdryNPbvvVUvbVr0d5Hf_j717DtoOnZFDL0xvY0OVbeDl2G_Dv4HRArPTpFXEVfkgTzlUtiIlTJ8IxXOfELPKSefVgY-zKH_I9TC4vvp4PPVeBwVOU88hTXKJHxrETCjU19wVPwzjN0SuMY8W5DGnCAyqLRJmEoghedIDwzxcsCWmUKEU_QKe8K_UeEFEIltOCFYgQIsZTGQqutcn_h1eUli4cN1zIlEtPbqpkTLPGTcHhyOxwdOFzSzqrc3L8jajXsDJzarnI0N9KGUfIgs2f2mZUKLNLIkqNQ5WZfECBOWCLNLu1CLRfoeagGvPjLhy2MvFUF44ti_9NkZ2NhvZm_1kv7EFnOa_0AcKgpfzoRP0342UEbQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+journey+through+infectious+risk+associated+with+ruxolitinib&rft.jtitle=British+journal+of+haematology&rft.au=Sant%E2%80%99Antonio%2C+Emanuela&rft.au=Bonifacio%2C+Massimiliano&rft.au=Breccia%2C+Massimo&rft.au=Rumi%2C+Elisa&rft.date=2019-11-01&rft.issn=0007-1048&rft.eissn=1365-2141&rft.volume=187&rft.issue=3&rft.spage=286&rft.epage=295&rft_id=info:doi/10.1111%2Fbjh.16174&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_bjh_16174 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1048&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1048&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1048&client=summon |